Equity Details
Price & Market Data
Price: $1.06
Daily Change: +$0.07 / 6.60%
Daily Range: $0.98 - $1.11
Market Cap: $5,729,806
Daily Volume: 276,390
Performance Metrics
1 Week: -17.29%
1 Month: -19.71%
3 Months: -79.42%
6 Months: -84.39%
1 Year: -93.68%
YTD: -75.54%
About FibroBiologics, Inc. (FBLG)
In-depth market report for FibroBiologics, Inc. (FBLG). The stock is valued at 1.06, with a daily change of +$0.07 / 6.60%. Market cap: 5,729,806. All key performance metrics are updated, including YTD and 52-week returns.
Company Details
Employees: 15
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.